A new study led by researchers at the Icahn School of Medicine at Mount Sinai has found that adding the targeted therapy ...

Cancer’s future may lie in combination therapy—pairing treatments to outsmart tumors, boost survival, and bring new hope ...

Pfizer said on Tuesday its cancer drug Padcev, in combination with Merck's Keytruda, significantly improved survival rates in ...

Researchers found that adding a third immune-targeting drug to existing therapies helped shrink tumors in lab models of ...

Treatment for advanced bladder cancer had not significantly changed for 40 years. Now thousands are set to benefit ...

Immune checkpoint blockade medications have revolutionized cancer treatment, giving patients and providers new hope to control and sometimes cure metastatic cancer. However, predicting which patients ...

Treating psoriatic arthritis (PsA) patients with more than one targeted therapy appears to be just fine, with no increased ...

The efficacy and safety of rivaroxaban monotherapy are consistent across all age groups of patients with atrial fibrillation and stable coronary artery disease, a study confirms.

Immunotherapy has been effective against some sarcomas, but the researchers need to understand how it would work in combination with epigenetic therapy. A successful combination with immunotherapy ...

In my opinion, combination therapy is here to stay, and has its own niche in the treatment of symptomatic BPH. CLICK HERE for subscription information about this journal.